Sanofi said it will not seek approval of amlitelimab in atopic dermatitis, citing the OX40-ligand antibody’s lack of meaningful improvement versus standard of care. The move reverses earlier expectations that amlitelimab could succeed as a next major franchise following Regeneron’s Dupixent.